1. Home
  2. HTFL vs PHVS Comparison

HTFL vs PHVS Comparison

Compare HTFL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartflow Inc.

HTFL

Heartflow Inc.

SELL

Current Price

$46.80

Market Cap

2.2B

Sector

N/A

ML Signal

SELL

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

SELL

Current Price

$32.14

Market Cap

2.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HTFL
PHVS
Founded
2007
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
HTFL
PHVS
Price
$46.80
$32.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
14
Target Price
★ $65.00
$58.05
AVG Volume (30 Days)
★ 1.7M
540.9K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.37
N/A
EPS
N/A
★ N/A
Revenue
★ $176,034,000.00
N/A
Revenue This Year
$49.74
N/A
Revenue Next Year
$24.54
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.92
N/A
52 Week Low
$20.13
$23.15
52 Week High
$60.66
$43.25

Technical Indicators

Market Signals
Indicator
HTFL
PHVS
Relative Strength Index (RSI) 38.96 44.47
Support Level $46.46 $25.67
Resistance Level $52.38 $36.14
Average True Range (ATR) 3.76 1.59
MACD -1.33 -0.09
Stochastic Oscillator 5.25 16.99

Price Performance

Historical Comparison
HTFL
PHVS

About HTFL Heartflow Inc.

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: